Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H D Preisler

Showing results (171-180 of 200) with videos related to

Pageof 20
Sort By:
Cytokine|June 14, 2000
SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patientsM Tao, B Li, J Nayini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cellsZ Q Wang, M Y Yin, X X Xie, et al.
British Journal of Haematology|August 1, 1986
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurementsH D Preisler, R Priore, N Azarnia, et al.
Blood|March 1, 1979
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimensH D Preisler, Y Rustum, E S Henderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemiaH D Preisler, T Gessner, N Azarnia, et al.
Auris, Nasus, Larynx|March 15, 2002
Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynxChristiane Kuropkat, T K Venkatesan, D D Caldarelli, et al.
British Journal of Haematology|September 1, 1984
Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinosideH D Preisler, J Epstein, M Barcos, et al.
Leukemia & Lymphoma|April 28, 2000
Telomerase activity in preleukemia and acute myelogenous leukemiaB Li, J Yang, C Andrews, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
Pageof 20

Showing results (171-180 of 200) with videos related to

Sort By:
Pageof 20
Cytokine|June 14, 2000
SCF, IL-1beta, IL-1ra and GM-CSF in the bone marrow and serum of normal individuals and of AML and CML patientsM Tao, B Li, J Nayini, et al.
European Journal of Cancer (Oxford, England : 1990)|January 1, 1990
Proto-oncogene expression in differentiating and non-differentiating chronic myelogenous leukaemia cellsZ Q Wang, M Y Yin, X X Xie, et al.
British Journal of Haematology|August 1, 1986
Prediction of response of patients with acute nonlymphocytic leukaemia to remission induction therapy: use of clinical measurementsH D Preisler, R Priore, N Azarnia, et al.
Blood|March 1, 1979
Treatment of acute nonlymphocytic leukemia: use of anthracycline-cytosine arabinoside induction therapy and comparison of two maintenance regimensH D Preisler, Y Rustum, E S Henderson, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1984
Relationship between plasma adriamycin levels and the outcome of remission induction therapy for acute nonlymphocytic leukemiaH D Preisler, T Gessner, N Azarnia, et al.
Auris, Nasus, Larynx|March 15, 2002
Abnormalities of molecular regulators of proliferation and apoptosis in carcinoma of the oral cavity and oropharynxChristiane Kuropkat, T K Venkatesan, D D Caldarelli, et al.
British Journal of Haematology|September 1, 1984
Prediction of response of acute nonlymphocytic leukaemia to therapy with 'high dose' cytosine arabinosideH D Preisler, J Epstein, M Barcos, et al.
Leukemia & Lymphoma|April 28, 2000
Telomerase activity in preleukemia and acute myelogenous leukemiaB Li, J Yang, C Andrews, et al.
British Journal of Haematology|November 1, 1991
The treatment of patients with newly diagnosed poor prognosis acute myelogenous leukaemia: response to treatment and treatment failureH D Preisler, R A Larson, A Raza, et al.
American Journal of Hematology|April 1, 1993
Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemiaA Raza, H D Preisler, Y Q Li, et al.
Pageof 20